Funding Opportunity RFA-DA-24-016 from the NIH Guide for Grants and Contracts. Only 1 in 10 people who need SUD treatment ever receive it. National survey data indicate that this treatment gap is largely driven by a misalignment between how treatment is designed (location, duration, structure, cost) and how patients prefer to engage in services. This FOA will support Patient Engagement Resource Centers to incorporate the perspectives of patients (including prospective patients, affected families, and persons in recovery) into research to inform the design and delivery of high quality treatment services that are responsive to their needs and preferences.

Notice NOT-MH-23-320 from the NIH Guide for Grants and Contracts

Notice NOT-HD-23-010 from the NIH Guide for Grants and Contracts

Notice NOT-HD-23-011 from the NIH Guide for Grants and Contracts

Notice NOT-DC-23-011 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-23-010 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to establish a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. Clinical Centers (CCs) will establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D.A separate NOFO (RFA-DK-23-009) will establish a Biostatistics Research Center (BRC) to oversee the development and coordination of a core protocol to be adopted by each CC awarded under the current NOFO (RFA-DK-23-010). The PI(s) of the BRC and the PIs from each of the CCs selected via RFA-DK-23-010 will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol across approximately 10 CCs and the BRC.Findings from this observational study are expected to advance our understanding of the impact of T1D on the developing brain and identify risk and protective factors associated with neurocognitive functioning to ultimately inform on effective strategies to decrease adverse neurodevelopmental outcomes and long-term neurocognitive sequelae of T1D.

Funding Opportunity RFA-DK-23-009 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. A separate RFA (RFA-DK-23-010 ) invites Clinical Centers (CCs) to establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will longitudinally evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D. The PI(s) of the BRC and the PIs from each of the CCs selected via RFA-DK-23-010 will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol across approximately 10 CCs and the BRC. Findings from this observational study are expected to advance our understanding of the impact of T1D on the developing brain and identify risk and protective factors associated with neurocognitive functioning to ultimately inform on effective strategies to decrease adverse neurodevelopmental outcomes and long-term neurocognitive sequelae of T1D.

Notice NOT-OD-23-130 from the NIH Guide for Grants and Contracts

£50000 - £60000 per annum: CK Group: CK Group are recruiting for a Senior Protein Scientist to join a biotechnology company based in London on a permanent basis. The Company: Our client... London

£45,737 - £54,421 including London Weighting Allowance.: Kings College London: Successful candidates are expected to establish their independent research group in the Centre.. london

Notice NOT-CA-23-068 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-066 from the NIH Guide for Grants and Contracts

Notice NOT-TW-23-006 from the NIH Guide for Grants and Contracts

Notice NOT-TW-23-005 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-024 from the NIH Guide for Grants and Contracts

£33,827- £36,606: Animal and Plant Health Agency: he APHA are seeking two research scientists with experience in molecular virology/ bioinformatic analysis and an interest in vector-borne... Weybridge, Surrey

Notice NOT-MH-23-325 from the NIH Guide for Grants and Contracts

Notice NOT-AA-23-012 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-23-172 from the NIH Guide for Grants and Contracts. The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This R34 Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a clinical trial within the scope of the companion announcement HIV Prevention and Alcohol (R01 Clinical Trials Optional). The NIAAA expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention of HIV. In this NIAAA funding opportunity for pilot clinical trials the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a clinical trial and testing of intervention tools.

Funding Opportunity PAS-23-173 from the NIH Guide for Grants and Contracts. The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This research activity includes the development and testing of new interventions and expansion of existing effective interventions as well as the implementation of these integrative preventive activities in diverse settings and populations. Six areas of research are of primary interest related to alcohol use and related mental health and substance use comorbidities. These include but are not limited to 1) PrEP Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Intervention Strategies, 4) Prevention-related Cross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and Operations Research.